2023原發(fā)性肝細胞癌的常用臨床分期

復雜，70%~90%的患者有長期慢性肝病史[2]。據(jù)估計，到2025年，每(AmericanJointCommitteeon表1肝細胞癌常用的臨床分期所包含的變量數(shù)目V數(shù)目VVVVVVVVVVVVVVVVVVVV淋巴結(jié)遠處轉(zhuǎn)移血管侵犯甲胎蛋白VVVVVVVVVVVVVVV√VVV√V√VVVVVVV√VVVVVVVV√VVVV√√V√VVVVVVVVVV√2.AJCC-TNM分期：2003年Kudo等[11]日本專家提出了JIS評分，將Child-Pugh分級和MESIAH評分是2012年由Mayo研究小組提出[14],納入的預后評估因SungH,Ferlayl,SiegelRL,etal.GlobalCancerStatistics2020:GLOShermanM.Hepatocellularcarcinoma:epidemiology,surveillance,anddiagnUoveUJM,KelleyRK,VillanuevaA,etalHepatocellularcarcinoma[J].NatRevDisPrimers,2016,14(2):16018.D0l:10.1038/nGaoQFanJ.Clonalheterogeneityandtumorevolutioninlivercancer:thecuttingedgeandthefuture[J]EdgeSB,ComptonCC.TheAmericanJointCommitteeonCancer:the7theditionoftheAJCCcancerstagingmanualaNoauthorslistedAnewprognosticsystemforhepatocellularcarcinoma:aretrospectivestudyof435pinvestigators[J].Hepatology,1998,28(3):751-755.DOl:10.1002/hep.510280322.UovetUM,BruC,BruixJ.Prognosisofhepatocellularcarcinoma:theBCLCstagingclassification[J].SeminLiverDis,1999,19(3):329-338.DOI:LeungTW,TangAM,ZeeB,etal.ConstructionoftheChineseUniversityPrognosticIndexforhepatocellularcarcinomeandcomparisonsystem,theOkudastagingsystem,andtheCanceroftheLiverItalianProgramstagingsystem:astudybaYauT,TangVY,YaoT),etal.DevelopmentofHongKongLiverCancerstagingsystemwithtreatmentstratificationforpatientswithhepatocellularcarcinoma[],Gastroenterology,2014,146(7):1691-1700.e3.DOI:10.1053/gastro.2014.02.032.Farinatif,VitaleA,SpolveratoG,etal.DevelopmentandvalidationofanewprognosticsystemforpatientswithhepatocellulXieDY,RenZG,Zhoul,etal.2019ChineseclinicalguidelinesforthemanagementofhepatocellularcarcinomaupdatesandinsiKinoshitaA,OnodaH,FushiyaN,etal.Stagingsystemsforhepatocellularcarcinoma:currentstatusandfutureperspectives[J]Tellapuris,SutphinPD,BegMS,etalStagingsystemsofhepatocellularcarcinoma:arevie